Duke is an innovative place to be! Explore some of our highlights from this past year
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio) announced an agreement under which Bayer will acquire AskBio, a U.S.-headquartered biopharmaceutical company specializing in the research, development and manufacturing of gene therapies across different therapeutic areas.
Duke University Redoubles Efforts to Convert Research Into Social Impact
With a sweeping administrative restructuring and new resources for technology transfer operations, Duke University will be enhancing the ability of faculty and staff to bring their scientific ideas into the marketplace and create new economic opportunities for the region and the nation.
UNC and Duke Team up to Launch Entrepreneurial Startup Hub
In the past, if you launched a startup in the Research Triangle region, daunting questions arrived faster than answers.
Bringing Inventions to the Market
Universities are great innovation incubators. Google, flu shots, vaccines, GPS, and many other inventions were born in university labs around the world and impact our lives every day.
IonQ and Evolv Go Public
IonQ, Inc., a leader in quantum computing, completed its previously announced business combination with dMY Technology Group, Inc. III, a publicly traded special purpose acquisition company, on September 30, 2021.
This Startup Just Raised $70 Million to Grow Tiny Tumors That Create Personalized Cancer Treatments
Around seven out of ten cancer patients don’t respond to drugs in the first go. This is a hard-hitting statistic for Xiling Shen, who lost his uncle to metastatic colorectal cancer.
Thermo Fisher Scientific Acquires Programmable Dye Platform Pioneer Phitonex
Thermo Fisher Scientific, the world leader in serving science, today announced it has completed the acquisition of Phitonex, Inc., a Durham, North Carolina-based company that has pioneered a spectral dye platform for high-resolution biology applications.
Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury
Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.
Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant
Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration.